201 related articles for article (PubMed ID: 32823651)
1. Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature.
Duhamel C; Ilie MD; Salle H; Nassouri AS; Gaillard S; Deluche E; Assaker R; Mortier L; Cortet C; Raverot G
J Pers Med; 2020 Aug; 10(3):. PubMed ID: 32823651
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review.
Ilie MD; Vasiljevic A; Jouanneau E; Raverot G
Endocr Relat Cancer; 2022 May; 29(7):415-426. PubMed ID: 35521777
[TBL] [Abstract][Full Text] [Related]
3. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Ilie MD; Villa C; Cuny T; Cortet C; Assie G; Baussart B; Cancel M; Chanson P; Decoudier B; Deluche E; Di Stefano AL; Drui D; Gaillard S; Goichot B; Huillard O; Joncour A; Larrieu-Ciron D; Libe R; Nars G; Vasiljevic A; Raverot G
Eur J Endocrinol; 2022 Nov; 187(5):685-696. PubMed ID: 36111659
[TBL] [Abstract][Full Text] [Related]
4. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
5. Aggressive corticotroph tumors and carcinomas.
Lasolle H; Vasiljevic A; Jouanneau E; Ilie MD; Raverot G
J Neuroendocrinol; 2022 Aug; 34(8):e13169. PubMed ID: 35979732
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art.
Feola T; Carbonara F; Verrico M; Di Crescenzo RM; Gianno F; Colonnese C; Arcella A; de Alcubierre D; Tomao S; Esposito V; Giangaspero F; Minniti G; Jaffrain-Rea ML
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077631
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.
Raverot G; Ilie MD
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101712. PubMed ID: 36274025
[TBL] [Abstract][Full Text] [Related]
8. Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.
van der Klaauw AA; Kienitz T; Strasburger CJ; Smit JW; Romijn JA
Pituitary; 2009; 12(1):57-69. PubMed ID: 18176844
[TBL] [Abstract][Full Text] [Related]
9. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
Lin AL; Jonsson P; Tabar V; Yang TJ; Cuaron J; Beal K; Cohen M; Postow M; Rosenblum M; Shia J; DeAngelis LM; Taylor BS; Young RJ; Geer EB
J Clin Endocrinol Metab; 2018 Oct; 103(10):3925-3930. PubMed ID: 30085142
[TBL] [Abstract][Full Text] [Related]
10. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.
Lidhar K; Korbonits M; Jordan S; Khalimova Z; Kaltsas G; Lu X; Clayton RN; Jenkins PJ; Monson JP; Besser GM; Lowe DG; Grossman AB
J Clin Endocrinol Metab; 1999 Oct; 84(10):3823-30. PubMed ID: 10523037
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
[TBL] [Abstract][Full Text] [Related]
12. Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
Nakano-Tateno T; Satou M; Inoshita N; van Landeghem FKH; Easaw J; Mehta V; Tateno T; Chik CL
Endocr Pathol; 2021 Sep; 32(3):418-426. PubMed ID: 32833164
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
14. Pituitary carcinoma - case series and review of the literature.
Du Four S; Van Der Veken J; Duerinck J; Vermeulen E; Andreescu CE; Bruneau M; Neyns B; Velthoven V; Velkeniers B
Front Endocrinol (Lausanne); 2022; 13():968692. PubMed ID: 36157469
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
[TBL] [Abstract][Full Text] [Related]
16. Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors under Temozolomide; Report of Three Cases and Review of the Literature.
Aydoğan Bİ; Ünlütürk U; Emral R; Güllü S
Turk Neurosurg; 2017 May; ():. PubMed ID: 28608351
[TBL] [Abstract][Full Text] [Related]
17. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Sol B; de Filette JMK; Awada G; Raeymaeckers S; Aspeslagh S; Andreescu CE; Neyns B; Velkeniers B
Eur J Endocrinol; 2021 Jan; 184(1):K1-K5. PubMed ID: 33112279
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
20. Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma.
Lin AL; Tabar V; Young RJ; Cohen M; Cuaron J; Yang TJ; Rosenblum M; Rudneva VA; Geer EB; Bodei L
J Endocr Soc; 2021 Oct; 5(10):bvab133. PubMed ID: 34466766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
